

Bilaga 1

Application No.	Category Description	Owners	Country	Date Filed	Expiry Date	Instructor	Case Ref.	Property Type	Registered Date	Registration No.
09764455.3	EP Validation	LIDDS AB	Netherlands	2009-Nov-27	2029-Nov-27	Lidds AB	21093750	Patent	2015-May-27	2376135
09764455.3	EP Validation	LIDDS AB	Switzerland-Liechtenstein	2009-Nov-27	2029-Nov-27	Lidds AB	21093753	Patent	2015-May-27	2376135
09764455.3	EP Validation	LIDDS AB	France	2009-Nov-27	2029-Nov-27	Lidds AB	21093747	Patent	2015-May-27	2376135
09764455.3	EP Validation	LIDDS AB	Germany	2009-Nov-27	2029-Nov-27	Lidds AB	21093748	Patent	2015-May-27	60 2009 031 447.5
09764455.3	EP Validation	LIDDS AB	Italy	2009-Nov-27	2029-Nov-27	Lidds AB	21093751	Patent	2015-May-27	502015000046307
09764455.3	EP Validation	LIDDS AB	Spain	2009-Nov-27	2029-Nov-27	Lidds AB	21093752	Patent	2015-May-27	2376135
09764455.3	EP Validation	LIDDS AB	Sweden	2009-Nov-27	2029-Nov-27	Lidds AB	21093754	Patent	2015-May-27	2376135
09764455.3	EP Validation	LIDDS AB	United Kingdom	2009-Nov-27	2029-Nov-27	Lidds AB	21104810	Patent	2022-Jun-09	10-2408805
10-2019-7011910	Normal via PCT National Phase	Lidds AB	Republic of Korea	2017-Oct-16	2037-Oct-16	Lidds AB	21093644	Patent	2015-Jan-20	8 996 809
11/910 162	Normal via PCT National Phase	LIDDS AB	USA	2006-Mar-31	2030-Jul-19	Lidds AB	21093687	Patent	2015-Apr-07	8 999 389
12/224 942	Normal via PCT National Phase	LIDDS AB	USA	2007-Mar-14	2029-Feb-15	Lidds AB	21093713	Patent	2015-Dec-01	9 198 884
2027	Normal via PCT National Phase	LIDDS AB	USA	2009-Nov-27	2030-May-12	Lidds AB	21093669	Patent	2015-May-19	9 034 359
13/405 887	Normal via PCT National Phase	LIDDS AB	USA	2004-Oct-21	2027-May-22	Lidds AB	21101671	Patent	2019-Jul-16	10 351 437
16/094 784	Normal via PCT National Phase	Lidds AB	USA	2017-Oct-16	2037-Oct-16	Lidds AB	21106530	Patent	2020-Apr-07	10 611 646
16/431 926	Divisional	Lidds AB	USA	2017-Oct-16	2037-Oct-16	Lidds AB	21104597	Patent	2019-Feb-27	3331826
17781521.4	EP Validation	Lidds AB	Czech Republic	2017-Oct-16	2037-Oct-16	Lidds AB	21104599	Patent	2019-Feb-27	3331826
17781521.4	EP Validation	Lidds AB	Denmark	2017-Oct-16	2037-Oct-16	Lidds AB	21104604	Patent	2019-Feb-27	3331826
17781521.4	EP Validation	Lidds AB	Finland	2017-Oct-16	2037-Oct-16	Lidds AB	21104605	Patent	2019-Feb-27	3331826
17781521.4	EP Validation	Lidds AB	Hungary	2017-Oct-16	2037-Oct-16	Lidds AB	21104607	Patent	2019-Feb-27	3331826
17781521.4	EP Validation	Lidds AB	Ireland	2017-Oct-16	2037-Oct-16	Lidds AB	21104608	Patent	2019-Feb-27	NO/EP3331826
17781521.4	EP Validation	Lidds AB	Netherlands	2017-Oct-16	2037-Oct-16	Lidds AB	21104596	Patent	2019-Feb-27	3331826
17781521.4	EP Validation	Lidds AB	Norway	2017-Oct-16	2037-Oct-16	Lidds AB	21104611	Patent	2019-Feb-27	3331826
17781521.4	EP Validation	Lidds AB	Switzerland-Liechtenstein	2017-Oct-16	2037-Oct-16	Lidds AB	21104610	Patent	2019-Feb-27	3331826
17781521.4	EP Validation	Lidds AB	Türkiye	2017-Oct-16	2037-Oct-16	Lidds AB	21104598	Patent	2019-Feb-27	60 2017 002 395.7
17781521.4	EP Validation	Lidds AB	France	2017-Oct-16	2037-Oct-16	Lidds AB	21104606	Patent	2019-Feb-27	502019000032955
17781521.4	EP Validation	Lidds AB	Germany	2017-Oct-16	2037-Oct-16	Lidds AB	21104600	Patent	2019-Feb-27	3331826
17781521.4	EP Validation	Lidds AB	Italy	2017-Oct-16	2037-Oct-16	Lidds AB	21104603	Patent	2019-Feb-27	3331826
17781521.4	EP Validation	Lidds AB	Spain	2017-Oct-16	2037-Oct-16	Lidds AB	21104609	Patent	2019-Feb-27	3331826
17781521.4	EP Validation	Lidds AB	Sweden	2017-Oct-16	2037-Oct-16	Lidds AB	21098619	Patent	2020-Feb-07	HK1253356
17781521.4	EP Validation	Lidds AB	United Kingdom	2017-Oct-16	2037-Oct-16	Lidds AB	21107607	Patent		
18112651.5	Normal	Lidds AB	Hong Kong	2017-Oct-16	2037-Oct-16	Lidds AB	21104078	Patent	2016-Dec-13	2 744 141
19129361.2	Normal	Lidds AB	Hong Kong	2017-Oct-16	2037-Oct-16	Lidds AB	21093720	Patent	2015-Oct-01	211732
19155030.5	Divisional	Lidds AB	EPC	2009-Nov-27	2029-Nov-27	Lidds AB	21093639	Patent	2015-Jun-01	330 414
2 744 141	Normal via PCT National Phase	LIDDS AB	Canada	2009-Sep-22	2029-Sep-22	Lidds AB	21093717	Patent	2015-Feb-27	5702294
20090211732	Normal via PCT National Phase	LIDDS AB	Israel	2009-Sep-22	2029-Sep-22	Lidds AB	21104809	Patent	2022-Jun-13	7088919
2011003257	Normal via PCT National Phase	LIDDS AB	Mexico	2009-Nov-27	2029-Nov-27	Lidds AB	21093115	Patent	2017-Dec-29	212624
2011-537896	Normal via PCT National Phase	LIDDS AB	Japan	2017-Oct-16	2037-Oct-16	Lidds AB	21104807	Patent	2022-Nov-03	266008
2019-520633	Normal via PCT National Phase	LIDDS AB	Japan	2017-Oct-16	2037-Oct-16	Lidds AB	21104805	Patent		
212624	Normal via PCT National Phase	LIDDS AB	Israel	2009-Nov-27	2029-Nov-27	Lidds AB	21104804	Patent	2023-Oct-03	1120190074783
266008	Normal via PCT National Phase	Lidds AB	Israel	2017-Oct-16	2037-Oct-16	Lidds AB	21093715	Patent	2015-May-20	330 183
3 038 699	Normal via PCT National Phase	Lidds AB	Canada	2017-Oct-16	2037-Oct-16	Lidds AB	21104811	Patent	2023-Oct-18	407259
BR 11 2019 007478 3	Normal via PCT National Phase	Lidds AB	Brazil	2017-Oct-16	2037-Oct-16	Lidds AB				
MX/a/2011/005243	Normal via PCT National Phase	LIDDS AB	Mexico	2009-Nov-27	2029-Nov-27	Lidds AB				
MX/a/2019/004414	Normal via PCT National Phase	Lidds AB	Mexico	2017-Oct-16	2037-Oct-16	Lidds AB				

Registration No.	Renewal date	Title	Instructor's Reference
2376135	Definitiv 30 Maj 2026	Use of carboxymethylcellulose to control ejectability and solidification time of compositions comprising one or more bioresorbable ceramics.	05CMC-PCT-EPNL
2376135	Definitiv 30 Maj 2026	Use of carboxymethylcellulose to control ejectability and solidification time of compositions comprising one or more bioresorbable ceramics.	05CMC-PCT-EPCHL
2376135	Definitiv 30 Maj 2026	Use of carboxymethylcellulose to control ejectability and solidification time of compositions comprising one or more bioresorbable ceramics.	05CMC-PCT-EPFR
60 2009 031 447.5	Definitiv 30 Maj 2026	Use of carboxymethylcellulose to control ejectability and solidification time of compositions comprising one or more bioresorbable ceramics.	05CMC-PCT-EPDE
502015000046307	Definitiv 30 Maj 2026	Use of carboxymethylcellulose to control ejectability and solidification time of compositions comprising one or more bioresorbable ceramics.	05CMC-PCT-EPIT
2376135	Definitiv 30 Maj 2026	Use of carboxymethylcellulose to control ejectability and solidification time of compositions comprising one or more bioresorbable ceramics.	05CMC-PCT-EPSE
2376135	Definitiv 30 Maj 2033	Use of carboxymethylcellulose to control ejectability and solidification time of compositions comprising one or more bioresorbable ceramics.	05CMC-PCT-EPGB
2376135	2026-06-09	A new method for producing calcium sulphate hemihydrate with unique properties	06HEAT-PCT-KR
10-2408805	2026-07-20	Method for treating prostate diseases based on local delivery of active substances.	02PROS-PCT-US
8 936 809	2026-10-07	Bioresorbable controlled-release composition.	03PRESS-PCT-US
8 999 389	2027-06-01	Use of carboxymethylcellulose to control ejectability and solidification time of compositions comprising one or more bioresorbable ceramics.	05CMC-PCT-US
9 198 884	2026-11-19	Composition comprising biodegradable hydrating ceramics for controlled drug delivery.	01ADD-PCT-US
9 034 359	2027-01-16	A new method for producing calcium sulphate hemihydrate with unique properties	06HEAT-PCT-US
10 351 437	2027-10-07	A new method for producing calcium sulphate hemihydrate with unique properties	06HEAT-PCT-US2
10 611 646	2026-04-16	A new method for producing calcium sulphate hemihydrate with unique properties	06HEAT-PCT-EPCZ
3331826	Definitiv 2026-04-16	A new method for producing calcium sulphate hemihydrate with unique properties	06HEAT-PCT-EPDK
3331826	Definitiv 2026-04-16	A new method for producing calcium sulphate hemihydrate with unique properties	06HEAT-PCT-EPFI
3331826	Definitiv 2026-04-16	A new method for producing calcium sulphate hemihydrate with unique properties	06HEAT-PCT-EPHU
3331826	Definitiv 2026-04-16	A new method for producing calcium sulphate hemihydrate with unique properties	06HEAT-PCT-EPJE
3331826	Definitiv 2026-04-16	A new method for producing calcium sulphate hemihydrate with unique properties	06HEAT-PCT-EPNL
NO/EP3331826	Definitiv 2026-04-16	A new method for producing calcium sulphate hemihydrate with unique properties	06HEAT-PCT-EPNO
3331826	Definitiv 2026-04-16	A new method for producing calcium sulphate hemihydrate with unique properties	06HEAT-PCT-EPCH
3331826	Definitiv 2026-04-16	A new method for producing calcium sulphate hemihydrate with unique properties	06HEAT-PCT-EPTR
3331826	Definitiv 2026-04-16	A new method for producing calcium sulphate hemihydrate with unique properties	06HEAT-PCT-EPFR
3331826	Definitiv 2026-04-16	A new method for producing calcium sulphate hemihydrate with unique properties	06HEAT-PCT-EPDE
60 2017 002 395.7	Definitiv 2026-04-16	A new method for producing calcium sulphate hemihydrate with unique properties	06HEAT-PCT-EPIT
502019000032955	Definitiv 2026-04-16	A new method for producing calcium sulphate hemihydrate with unique properties	06HEAT-PCT-EPES
3331826	Definitiv 2026-04-16	A new method for producing calcium sulphate hemihydrate with unique properties	06HEAT-PCT-EPSE
3331826	Definitiv 2026-04-16	A new method for producing calcium sulphate hemihydrate with unique properties	06HEAT-PCT-EPGB
3331826	Definitiv 2026-04-16	A new method for producing calcium sulphate hemihydrate with unique properties	06HEAT-PCT-EPPL
3331826	Definitiv 2026-04-16	A new method for producing calcium sulphate hemihydrate with unique properties	06HEAT-PCT-EPHK
HK1253356	Definitiv 2026-04-16	A new method for producing calcium sulphate hemihydrate with unique properties	06HEAT-PCT-EP2HK
2 744 141	Definitiv 2026-05-27	A new method for producing calcium sulphate hemihydrate with unique properties	06HEAT-PCT-EP2
211732	2027-09-22	Injector device	05CMC-PCT-CA
330 414	Definitiv 2026-03-22	Injector device	04MIX-PCT-IL
5702294	2026-02-27	Use of carboxymethylcellulose to control ejectability and solidification time of compositions comprising one or more bioresorbable ceramics.	04MIX-PCT-MX
7088919	2026-06-13	A new method for producing calcium sulphate hemihydrate with unique properties	05CMC-PCT-IP
212624	2027-11-27	Use of carboxymethylcellulose to control ejectability and solidification time of compositions comprising one or more bioresorbable ceramics	06HEAT-PCT-IP
266008	2027-10-16	A new method for producing calcium sulphate hemihydrate with unique properties	05CMC-PCT-IL
1120190074783	Definitiv 2026-04-16	A new method for producing calcium sulphate hemihydrate with unique properties	06HEAT-PCT-IL
330 183	Definitiv 2026-04-16	A new method for producing calcium sulphate hemihydrate with unique properties	06HEAT-PCT-CA
407259	Definitiv 2026-05-27	Use of carboxymethylcellulose to control ejectability and solidification time of compositions comprising one or more bioresorbable ceramics.	06HEAT-PCT-BR
	2028-10-16	A new method for producing calcium sulphate hemihydrate with unique properties	05CMC-PCT-MX
			06HEAT-PCT-MX

Bilaga 2

Application No.	Category Description	Owners	Country	Date Filed	Expiry Date	Instructor	Case Ref.	Property Type	Registered Date	Registration No.
201280014101.3	Normal via PCT National Phase	Noviga Research AB	China	2012-Mar-23	2032-Mar-23	Noviga Research AB	21148030	Patent	2016-Nov-30	ZL201280014101.3
3095709	Normal via PCT National Phase	Noviga Research AB	Canada	2019-Apr-04	2039-Apr-04	Noviga Research AB	21148027	Patent		
2014500409	Normal via PCT National Phase	Noviga Research AB	Japan	2012-Mar-23	2032-Mar-23	Noviga Research AB	21148029	Patent	2016-Feb-19	5886411
19781419.7	EP Validation	Noviga Research AB	United Kingdom	2019-Apr-04	2039-Apr-04	Noviga Research AB	21154874	Patent	2025-Sep-10	3773592
12710277.0	EP Validation	Noviga Research AB	Germany	2012-Mar-23	2032-Mar-23	Noviga Research AB	21148040	Patent	2016-May-18	2688883
12710277.0	EP Validation	Noviga Research AB	Spain	2012-Mar-23	2032-Mar-23	Noviga Research AB	21148038	Patent	2016-May-18	2688883
12710277.0	EP Validation	Noviga Research AB	France	2012-Mar-23	2032-Mar-23	Noviga Research AB	21148036	Patent	2016-May-18	2688883
12710277.0	EP Validation	Noviga Research AB	United Kingdom	2012-Mar-23	2032-Mar-23	Noviga Research AB	21148035	Patent	2016-May-18	2688883
12710277.0	EP Validation	Noviga Research AB	Italy	2012-Mar-23	2032-Mar-23	Noviga Research AB	21148034	Patent	2016-May-18	502016000098484
12710277.0	EP Validation	Noviga Research AB	Sweden	2012-Mar-23	2032-Mar-23	Noviga Research AB	21148032	Patent	2016-May-18	2688883
2830129	Normal via PCT National Phase	Noviga Research AB	Canada	2012-Mar-23	2032-Mar-23	Noviga Research AB	21148031	Patent	2016-Jul-19	2830129
2020-551269	Normal via PCT National Phase	Noviga Research AB	Japan	2019-Apr-04	2039-Apr-04	Noviga Research AB	21148025	Patent	2023-Oct-23	7372253
16/981232	Normal via PCT National Phase	Noviga Research AB	USA	2019-Apr-04	2039-Apr-04	Noviga Research AB	21148024	Patent	2023-Feb-28	11590130
14/005889	Normal via PCT National Phase	Noviga Research AB	USA	2012-Mar-23	2032-Mar-23	Noviga Research AB	21148028	Patent	2015-Apr-14	9006241

Registration No.	Renewal Date	Abandonment Date	Title	Instructor's Reference
ZL201280014101.3	2026-03-23	2025-Dec-10	Pyrimidine derivatives	Novel Pyrimidine Derivatives-P-PC-CN
	2026-04-04	2025-Jul-28	Novel combination	Novel combination-PC-CA
5886411	2026-02-19	2025-Oct-29	Pyrimidine derivatives	Novel Pyrimidine Derivatives-P-PC-IP
3773592	2026-04-31	2026-Jan-05	NOVEL COMBINATIONS OF A TUBULIN POLYMERIZATION INHIBITOR AND A POLY (ADP-RIBOSE) POLYMERASE (PARP) INHIBITOR FOR USE IN THE TREATMENT OF CANCER	Novel combination-PC-EP-UK
2688883	2026-03-31	2026-Jan-05	Pyrimidine derivatives	Novel Pyrimidine Derivatives-EP-DE
2688883	2026-03-31	2026-Jan-05	Pyrimidine derivatives	Novel Pyrimidine Derivatives-EP-ES
2688883	2026-03-31	2026-Jan-05	Pyrimidine derivatives	Novel Pyrimidine Derivatives--EP-FR
2688883	2026-03-31	2026-Jan-05	Pyrimidine derivatives	Novel Pyrimidine Derivatives-EP-GB
502016000098484	2026-03-31	2026-Jan-05	Pyrimidine derivatives	Novel Pyrimidine Derivatives-EP-IT
2688883	2026-03-31	2026-Jan-05	Pyrimidine derivatives	Novel Pyrimidine Derivatives-EP-SE
2830129	2026-03-23	2026-Jan-05	Pyrimidine derivatives	Novel Pyrimidine Derivatives-P-PC-CA
7372253	2026-10-23	2026-Jan-13	Novel combination	Novel combination-PC-JP
11590130	2026-08-28	2026-Jan-13	Novel combination	Novel combination-PC-US
9006241	2026-10-14	2026-Jan-13	Pyrimidine derivatives	Novel Pyrimidine Derivatives-P-PC-US

Företagens historia

FÖRENINGEN FÖRETAGENS HISTORIA UPPSALA LÄN

LEVERANSREVERSAL

Företagens historia har den 14 januari 2015 tagit emot följande material ifrån LIDDS AB:

Handling	Antal
Sektion 118:1	
Patent method for treating prostate diseases	6
Patent Composition composing Hydrating Ceramics	3
Patent Medical use of Biodegradable Ceramics	1
Patent Bioresorbable controlled-released composition	1
Quality documentation	1
Liproca® Depot Clinical study LPC-003 Application & Amendment 1 2011	1
Sektion 118:2	
RCC Harlan Study no B77938, B83070	1
R&D Reports 2004-2008	3
Quality Documentation APL and Syntagen	2
2-Hydroxy-flutamide Syntagen	1
Klinikdokument LPC-003	1
LPC-002 Investigator's meeting	1
LIDDS 2 (LPC-002 bl a dokument på finska, läkemedelstillstånd, Clinical trial mm)	1
Clinical Trial LPC-001 Amendment Finland	1
Liproca Impant APL documentation batch 2137874	1
Clinical Trial LPC-001 Application & Approval MBA Finland 2006-2007	1
Sektion 118:3	
Clinical Trial LPC-001 Application & Approval EPN Finland 2006-2007	1
Clinical Trial LPC-001 Application & Approval MPA Sweden 2006-2007	1
Clinical Trial LPC-001 Amendments Sweden	1
Study Master File LPC-001	5
CD: eSMF LPC-001	1
CD: The EORTC QLQ-C30 Manuals, Reference values mm	1
Agreement Litigations C6	1
Employees C5	1
Insurance, Executive, Company Group C4	1
Agreements Clinical, Non Clinical C6	1
Agreements Others C6	1
Sektion 118:4	
Agreement Confidentiality	
Agreement Pharmaceutical Dev. (Formulation, device, GMP, API)	1
Intellectual properties	
Lab Scantox study no 60297 Draft report	

Patent Bioresorbable controlled release composition
 2-hydroxyflutamide study no 60297 Lab Scantox
 CD: LPC-002 CSR Appendices
 CD: Hundstudie 1 Harlan bilder
 CD: Study no B77938 Sektionsfoton Prostate
 CD: Lab Scantox Test Report Study no 60297 2007
 Buntar: Liproca® Depot Report

Sektion 118:5

Patent Injector Devise National Applications	2
Patent Injector Devise	1
Patent Use of CMC to control ejectability and solidification	1
Patent Use of CMC to control ejectability and solidification Nat. Applications	2
Patent Bioresorbable controlled release composition	4
Mapp: Brev ang bevakningsregister – ej aktuellt att bevaka längre Patrafée	1

Sektion 118:6

Aktieägaravtal I & II, Skattekonsekvenser	1
Aktieägaravtal	1
Insurance Clinical	1
Financial information	2
Development of Share Capital	1
Shareholders meeting	1
General information	2
Board meetings	3
Patent	1
Verifikationer 2007	2
Leverantörsfakturor 2007	1

Sektion 118:7

Leverantörsfakturor 2008	3
Redovisning 2008	1
Verifikationer 2008	2
Årsredovisningar, deklARATIONER, bokslutsbilagor	1
DM file LPC-002 part I & II	1
Summary Basis of Approval Casodex NDA-20-498 1994	1
Innovative and targeted cancer therapies	1
Prostate cancer China Decision Resources	1
Pipeliner Insight: prostate cancer (Datamonitor)	1
Prospekt Emissioner 2004-2014	1
Mapp: Data Management Study Doc Delivery	1

Sektion 118:8

Study code LPC-002 CRF's	8
LPC-003 Interim Study Reports 2014	1
Redovisning 2009	1
Årsredovisning, bokslutsbilagor, deklARATIONER 2008	1
Verifikationer 2009	2

Sektion 118:9

Leverantörsfakturor 2009	4
--------------------------	---

Årsbokslut	1
Datamonitor Commercial insight Antihormonal therapy cancer brands	1
Pipeline insight: Prostate cancer	1
Stake holders insight: Prostate cancer	1
The Cancer Market Outlook to 2011	1
1 kartong: Inbjudan till teckning av units LIDDS AB, anmälningssedlar	1
2-Hydroxy-flutamide DuPont Chemoswed	1

Sektion 118:10

Grundakt	1
Verifikationer 2006	4
Verifikationer 2007 (jan-sep)	3
Redovisning 2005-2006	1
Redovisning 2007	1
556580-2856 (kvitton, fakturor mm 2003-2004)	1
Verifikationer 2005	2
1 kartong: Inbjudan till teckning av units Lidds AB	1

Sektion 118:11

1 kartong: K20/05 Bio Vet Histologipreparat	1
1 kartong: K20/05 Vävnadsprover i paraffin	1
1 låda: Dokumentation av försök utförda för LIDDS räkning, kopior, labjournaler	1
1 låda: Klossar, glas (återsänt material), CDs/DVDs: film LIDDS Liproca®, brev till aktieägare, Ethics committees documents mm	1

Sektion 118:12

LPC-002 Trial Master File	7
LPC-002 TMF Correspondence	1
Verifikationer 2010	3

Sektion 118:13


Leverantörsfakturor 2010	4
Redovisning 2010	1
Årsbokslut 2010	1
Leverantörsfakturor 2011	4
Verifikationer 2011	3
Årsbokslut 2011	1
Redovisning 2011	1

Sektion 118:14

Verifikationer 2012	2
Leverantörsfakturor 2012	3
Redovisning 2012	1
Årsbokslut 2012	1

Materialet omfattar 13,5 hyllmeter.

Uppsala den 19 januari 2015



Ulrika Andersson
Arkivarie Företagens historia

LEVERANSREVERSAL

Företagens historia har i april tagit emot följande material ifrån LIDDS AB:

Handling	Antal
Sektion 108:18-19	
Plomberad box med nr 012004 (CRF's)	1
Plomberad box med nr 012005 (CRF's)	1
Plomberad box med nr 012006 (CRF's, Inv. Study file)	1
Plomberad box med nr 012011 (Inv. Study file)	1
Plomberad box med nr 012012 (Inv. Study file)	1
Plomberad box med nr 012013 (Inv. Study file)	1
Plomberad box med nr 012014 (Inv. Study file)	1
Plomberad box med nr 012016 (Inv. Study file)	1
Plomberad box med nr 012017 (CRF's)	1
Plomberad box med nr 012018	1
Plomberad box med nr 003987	1
Plomberad box med nr 003988	1
Sektion 108:20	
LPC-002 EC 1-2/2	2
LPC-002 Finland Project correspondence	1
LPC-002 Finland Regulatory (NAM/FIMEA)	1
LPC-001 Site 02	1
LPC-001 ISF No 2 Tampere, Tammela 1 (4)	1
LPC-001 ISF No 2 Tampere, Tammela 2 (4)	1
LPC-001 ISF No 2 Tampere, Tammela 3 (4)	1
LPC-001 ISF No 2 Tampere, Tammela, CRF's 4 (4)	1

Materialiet omfattar 2 hyllmeter.

Uppsala i juni 2015



Ulrika Andersson

Arkivarie Företagens historia

LEVERANSREVERSAL

Idag har Föreningen Företagens historia ifrån **LIDDS AB** tagit emot följande material:

Handling	År	Antal boxar
LPC - 003 TMF Binder 1	2011-001137-16	1
LPC - 003 TMF Binder 2 Tampere, Tammela Binder 2/4	2011-001137-16	1
LPC - 003 TMF Binder 3 Study interim report	2011-001137-16	1
LPC - 003 TMF Binder 4 CRF copies	2011-001137-16	1
LPC -003 TMF Binder 5 Correspondence, monitor	2011-001137-16	1
LPC-003 TMF Binder 6 Correspondence, monitor	2011-001137-16	1
LPC-003 Part II TMF Binder7 Final study report	2011-001137-16	1
LPC-003 Finland FIMEA and IRB submissions	-	
SMF LPC-003	2011-001137-16	
LPC-003 Sweden EPN Submissions	-	1
CRF LPC-003 Sweden EPN Submissions	-	1
LPC-003 Including amended study	2014-2015	1
LPC-003 Site 01	-	1

LPC-003 Site 02	-	1
LPC-003 Site 02 Transmittal forms	-	1

Arkivhandlingarna omfattar ca 1,5 hyllmeter och förvaras hos Företagens historia i Uppsala Business Park.

Uppsala den 25 januari 2016



Maria Thysell
Arkivchef Företagens historia

Bilaga 4

Placering Pärnmamn

F107:1 LIDDS Patent Stefan Grudén
F107:1 LIDDS External Projects Stefan Grudén
F107:1 LIDDS Internal Projects Stefan Grudén
F107:1 LIDDS AB18-16 LIDDS vehicle Local tolerance Adlego Biomedical
F107:1 LIDDS AB18-68 B16-F10 tumours STING NZ-STING Adlego Biomedical
F107:1 AB19-08 LIDDS Final Report Adlego Biomedical
F107:1 LIDDS AB19-08 NZ-MTX CT26 Tumours Adlego Biomedical
F107:1 Omärkt pärm
F107:1 Omärkt pärm
F107:1 Patents Zacco Förnyelsekvitton
F107:1 2014 Utrustning
F107:1 LIDDS Kontakter 2006 N. Axén
F107:1 LIDDS Kontakter (Inköp) 2010-2017 N. Axén
F107:1 Anteckningsbok Stefan Grudén LIDDS AB Jan 2018 - Mar 2020
F107:1 Anteckningsbok Stefan Grudén LIDDS AB Mar 2020 - Apr 2022
F107:1 Anteckningsbok Stefan Grudén LIDDS AB Apr 2022 - Jun 2022
F107:1 Laboratoriejournal Uppsala Universitet
F107:1 LIDDS Labböcker -2008 N. Axén
F107:1 Patent Albihns N. Axén
F107:1 Patent Albihns N. Axén
F107:2 LIDDS Patent Flutaguid o. d. N. Axén 2005
F107:2 Artiklar Cytostatica N. Axén
F107:2 Frauke LIDDS 2008
F107:2 LIDDS Marknadsrapport N. Axén
F107:2 LIDDS Kontakter 2004-2005 N. Axén
F107:2 Omärkt pärm
F107:2 Omärkt pärm (LIDDS Årsredovisning 2022)
F107:2 Årsredovisning LIDDS AB 2014
F107:2 LIDDS SHB KU och avräkningsnotor 2016
F107:2 Omärkt pärm
F107:2 LIDDS AB Utbetalningar U-I- 2019
F107:2 LIDDS AB Journaler LEV och UTBET 2019
F107:2 LIDDS AB Finansiella rapporter
F107:2 LIDDS AB Leverantörer 2019 01-02
F107:2 Omärkt pärm
F107:2 Lev. fakturor december 2019
F107:2 LIDDS AB Lev.fakt. oktober- 2019
F107:2 LIDDS AB 2019 Verifikationer aug-sept
F107:3 LIDDS AB ver. pärm okt-dec 2019
F107:3 LIDDS AB Personal
F107:3 LIDDS Instruktioner och Policies Arb. Ex BN
F107:3 Emission 2020:1
F107:3 NE 201982
F107:3 LIDDS TI 2017/2020
F107:3 LIDDS NE 2018-1 NE 2018-2 Riktade NE
F107:3 LIDDS XBS 2017-10-06
F107:3 LIDDS NE 2017 Företrädes-
F107:3 LIDDS NE 2017-2 Riktad NE
F107:3 LIDDS NE 2015 Riktad NE TO 1
F107:3 LIDDS Årsredovisning 2016
F107:3 LIDDS Årsstämma 2016 2016-04-22
F107:3 LIDDS Budget 2017
F107:3 LIDDS AB Stämmoprotokoll
F107:3 LIDDS Extra årsstämma 2016 2016-06-09
F107:3 LIDDS Årsstämma 2017 2017-05-11
F107:3 LIDDS AB 556580-2856 Bolagstämmor underlag 2018-2020
F107:4 LIDDS AB Avstämningar Kundnr: 224 2019-01-01 2019-12-31
F107:4 LIDDS AB Bokföringsverifikat 2019 Jan-Juli

F107:4 LIDDS AB 2019 Lev. fakt. 08-09 2019
F107:4 LIDDS AB Leverantörer 2019 03-04
F107:4 Omärkt pärm
F107:4 LIDDS Bakgrundsmaterial Sept.-14 T. Julin
F107:4 LIDDS Projekt Avtal
F107:4 Betalningsunderlag 2017 2018 2019
F107:4 LIDDS Diverse - korr - myndigheter - ref.
F107:4 Div Adm.
F107:4 LIDDS 2015 LPC-001 LPC-002
F107:4 LIDDS 2016 LV meeting
F107:4 Liproca Implant Ansökan om klinisk prövning Studie nr LPC-001 EudraCT nr 2006-006365-17 LIDDS AB Dec 2006
F107:4 LIDDS Styrelseprotokoll 2019-2020
F107:4 LIDDS Styrelseprotokoll 2018
F107:4 LIDDS Styrelseprotokoll 2016-2017
F107:4 LIDDS Styrelseprotokoll 2015
F107:5 Årsakt 2021
F107:5 LIDDS Årsakt 2022
F107:5 LIDDS AB Leverantörer 2018 04-06
F107:5 LIDDS AB Leverantörer 2018 01-03
F107:5 LIDDS AB Leverantörer 2018 10-12
F107:5 LIDDS Årsark 2023
F107:5 Omärkt pärm
F107:5 LIDDS 2016 LPC-003 P&R
F107:5 LIDDS 2015 LPC-003 part 2
F107:5 LIDDS AB22-27 NanoZolid EMT6 Adlego Biomedical
F107:5 LIDDS Investigator meeting March 24-25 2017 LPC-004
F107:5 Huskataloger
F107:5 Omärkt pärm
F107:5 LIDDS Pharma AB
F107:5 Omärkt pärm
F107:5 LIDDS AB Leverantörer 2020 07-
F107:6 LIDDS AB Bokföringsverifikat 2020 01-06
F107:6 LIDDS AB Journaler LEV och UTBET 2020
F107:6 Leverantörer 2021 01-03
F107:6 LIDDS AB Bokföringsverifikat Utbetalningar U-serie 2020 01-12
F107:6 LIDDS AB Leverantörer 2020 01-03
F107:6 LIDDS AB Avstämningar Kundnr: 224 2020-01-01 2020-12-31
F107:6 LIDDS AB Bokföringsverifikat 2020 07-12
F107:6 LIDDS AB Deklarationer och skatt
F107:6 Bolagshandlingar
F107:6 LIDDS AB 556580-2856 Avtal 6
F107:6 LIDDS Avtal LPC-004
F107:6 LIDDS Avtal Anställda Konsulter
F107:6 LIDDS Bokslut 2017
F107:6 LIDDS Leverantörer 2017 01-05
F107:6 LIDDS AB Leverantörer 2018 05-07
F107:6 Widgrens Bokföringsbyrå AB Avstämningar Kundnr: 224 LIDDS AB 2017-01-01 2017-12-31
F107:21 LIDDS HB VER 1501-1505
F107:21 LIDDS Bokslut 2016
F107:21 LIDDS 2015 LEV 1505-1510-1512
F107:21 LIDDS 2015 LEV 1501-1504
F107:21 LIDDS 2016 LEV 1605-1612
F107:21 LIDDS 2016 LEV 1601-1604
F107:21 LIDDS 2014 HB VER 1401-1410
F107:21 LIDDS 2014 VER 2014
F107:22 LIDDS Bokföringsverifikat 2017
F107:22 LIDDS Bokföringsverifikat 2017 forts
F107:22 LIDDS Leverantörer 2017 06-
F107:22 LIDDS Journaler LEV och UTBET 2017 2018
F107:22 LIDDS AB Avstämningar 2018-01-01 2018-12-31
F107:22 LIDDS AB Leverantörer 2018 07-09

F107:22 LIDDS AB 556580-2856 Avtal 1 Fr Aug 2017
F107:22 LIDDS AB Bokföringsverifikat 2018 1/2
F107:22 LIDDS AB Bokföringsverifikat 2018 2/2
F107:22 Bokslut 2018 2018-01-01 2018-12-31
F107:22 Bokslut 2019 2019-01-01 2019-12-31
F107:22 ANJA Div. underlag Bokslut 2019
F107:23 Q3 2019
F107:23 LIDDS Leverantörer 2017 10-12
F107:23 LIDDS AB Leverantörer 2020 04-06
F107:23 Skatteverket 2020 Underlag + Utlägg
F107:23 LIDDS Pharma AB 2019
F107:23 LIDDS AB 556580-2856 Avtal 2 Admin
F107:23 Rubrik Avtal 3 Licensavtal Kina
F107:23 LIDDS Avtal Sekretessavtal 4
F107:23 LIDDS AB 556580-2856 Samarbetsavtal 5
F107:23 LIDDS Avtal Avslutade/Uppsagda
F107:23 LIDDS 2014 LEV 1401-1404
F107:23 LIDDS 2013 LEV 1307-1312